VIRGINIA RETIREMENT SYSTEMS ET Al Invests $2.17 Million in TG Therapeutics, Inc. $TGTX

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 39,531 shares of the biopharmaceutical company’s stock, valued at approximately $2,172,000.

Several other hedge funds have also modified their holdings of TGTX. EverSource Wealth Advisors LLC boosted its holdings in TG Therapeutics by 51.9% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 365 shares during the period. Maryland State Retirement & Pension System raised its stake in shares of TG Therapeutics by 2.0% during the fourth quarter. Maryland State Retirement & Pension System now owns 19,899 shares of the biopharmaceutical company’s stock valued at $593,000 after purchasing an additional 393 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of TG Therapeutics by 1.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 31,406 shares of the biopharmaceutical company’s stock valued at $1,135,000 after purchasing an additional 441 shares during the period. Smartleaf Asset Management LLC lifted its position in shares of TG Therapeutics by 16.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 3,147 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 454 shares in the last quarter. Finally, HB Wealth Management LLC lifted its position in shares of TG Therapeutics by 6.7% during the first quarter. HB Wealth Management LLC now owns 7,514 shares of the biopharmaceutical company’s stock worth $250,000 after purchasing an additional 475 shares in the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Stock Up 1.4%

Shares of NASDAQ:TGTX opened at $55.39 on Friday. The firm has a market cap of $8.48 billion, a PE ratio of 20.22, a price-to-earnings-growth ratio of 2.34 and a beta of 1.67. The company has a fifty day simple moving average of $53.63 and a 200 day simple moving average of $43.61. The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23. TG Therapeutics, Inc. has a 12-month low of $26.76 and a 12-month high of $59.30.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.26). The company had revenue of $240.34 million for the quarter, compared to analyst estimates of $229.77 million. TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%.TG Therapeutics’s revenue was up 70.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.17 earnings per share. On average, equities research analysts anticipate that TG Therapeutics, Inc. will post 0.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $83.00 price target on shares of TG Therapeutics in a report on Monday, June 22nd. Weiss Ratings reiterated a “hold (c+)” rating on shares of TG Therapeutics in a report on Wednesday, July 29th. HC Wainwright restated a “buy” rating and set a $78.00 target price on shares of TG Therapeutics in a research note on Tuesday, September 1st. Bank of America lifted their target price on TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a research report on Tuesday, July 7th. Finally, Zacks Research cut TG Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $63.00.

TG Therapeutics Profile

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for B-cell diseases and autoimmune disorders. The company’s research and development programs are centered on therapies that target B cells, which play an important role in several immune-mediated conditions.

TG Therapeutics’ principal product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved by the U.S. Food and Drug Administration for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis.